An optimized intranasal LNP formulation for potent immune responses of mRNA-based RSV vaccines.

Nasal immunoglobulin A (IgA) has been shown to be associated with the prevention of respiratory syncytial virus (RSV) infection and viral replication. However, generating strong mucosal IgA for mRNA vaccines administered via intramuscular injection h…

Preview only. Read the full abstract at the source